177 related articles for article (PubMed ID: 17612524)
1. Lobelane decreases methamphetamine self-administration in rats.
Neugebauer NM; Harrod SB; Stairs DJ; Crooks PA; Dwoskin LP; Bardo MT
Eur J Pharmacol; 2007 Sep; 571(1):33-8. PubMed ID: 17612524
[TBL] [Abstract][Full Text] [Related]
2. Lobeline attenuates d-methamphetamine self-administration in rats.
Harrod SB; Dwoskin LP; Crooks PA; Klebaur JE; Bardo MT
J Pharmacol Exp Ther; 2001 Jul; 298(1):172-9. PubMed ID: 11408539
[TBL] [Abstract][Full Text] [Related]
3. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
Beckmann JS; Siripurapu KB; Nickell JR; Horton DB; Denehy ED; Vartak A; Crooks PA; Dwoskin LP; Bardo MT
J Pharmacol Exp Ther; 2010 Dec; 335(3):841-51. PubMed ID: 20805303
[TBL] [Abstract][Full Text] [Related]
4. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
[TBL] [Abstract][Full Text] [Related]
5. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
[TBL] [Abstract][Full Text] [Related]
6. Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.
Kangiser MM; Dwoskin LP; Zheng G; Crooks PA; Stairs DJ
Behav Pharmacol; 2018 Feb; 29(1):87-97. PubMed ID: 28863003
[TBL] [Abstract][Full Text] [Related]
7. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
Nickell JR; Siripurapu KB; Vartak A; Crooks PA; Dwoskin LP
Adv Pharmacol; 2014; 69():71-106. PubMed ID: 24484975
[TBL] [Abstract][Full Text] [Related]
8. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.
Beckmann JS; Denehy ED; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2012 Mar; 220(2):395-403. PubMed ID: 21938414
[TBL] [Abstract][Full Text] [Related]
9. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.
Wilmouth CE; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Pharmacol Biochem Behav; 2013 Nov; 112():29-33. PubMed ID: 24075974
[TBL] [Abstract][Full Text] [Related]
10. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
[TBL] [Abstract][Full Text] [Related]
11. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
[TBL] [Abstract][Full Text] [Related]
12. Effect of bupropion on nicotine self-administration in rats.
Rauhut AS; Neugebauer N; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2003 Aug; 169(1):1-9. PubMed ID: 12811464
[TBL] [Abstract][Full Text] [Related]
13. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.
Nickell JR; Siripurapu KB; Horton DB; Zheng G; Crooks PA; Dwoskin LP
Eur J Pharmacol; 2017 Jan; 795():143-149. PubMed ID: 27986625
[TBL] [Abstract][Full Text] [Related]
14. Lobeline does not serve as a reinforcer in rats.
Harrod SB; Dwoskin LP; Green TA; Gehrke BJ; Bardo MT
Psychopharmacology (Berl); 2003 Feb; 165(4):397-404. PubMed ID: 12459929
[TBL] [Abstract][Full Text] [Related]
15. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Horton DB; Siripurapu KB; Norrholm SD; Culver JP; Hojahmat M; Beckmann JS; Harrod SB; Deaciuc AG; Bardo MT; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):940-51. PubMed ID: 21177475
[TBL] [Abstract][Full Text] [Related]
16. Bupropion attenuates methamphetamine self-administration in adult male rats.
Reichel CM; Murray JE; Grant KM; Bevins RA
Drug Alcohol Depend; 2009 Feb; 100(1-2):54-62. PubMed ID: 19010609
[TBL] [Abstract][Full Text] [Related]
17. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats.
Carson DS; Cornish JL; Guastella AJ; Hunt GE; McGregor IS
Neuropharmacology; 2010 Jan; 58(1):38-43. PubMed ID: 19560473
[TBL] [Abstract][Full Text] [Related]
18. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.
Zheng G; Dwoskin LP; Deaciuc AG; Norrholm SD; Crooks PA
J Med Chem; 2005 Aug; 48(17):5551-60. PubMed ID: 16107155
[TBL] [Abstract][Full Text] [Related]
19. The effect of N-acetylcysteine or bupropion on methamphetamine self-administration and methamphetamine-triggered reinstatement of female rats.
Charntikov S; Pittenger ST; Pudiak CM; Bevins RA
Neuropharmacology; 2018 Jun; 135():487-495. PubMed ID: 29604294
[TBL] [Abstract][Full Text] [Related]
20. Effects of methamphetamine isomers on d-methamphetamine self-administration and food-maintained responding in male rats.
Bardo MT; Denehy ED; Hammerslag LR; Dwoskin LP; Blough BE; Landavazo A; Bergman J; Kohut SJ
Psychopharmacology (Berl); 2019 Dec; 236(12):3557-3565. PubMed ID: 31346628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
